Phase one and 2 ZoptEC were VERY successful
- Phase 2 showed twice the survival rate of endometrial cancer (EC) than the only available non-specific multi-billion dollar drug doxorubicin
- Phase 3 successful 1st and 2nd DSMB reviews. The third and last one about 2 to 3 months from now
.....This prompted UT Southwestern University (currently participating in Phase 3 trials) to proclaim That "zoptarelin doxorubicin (AEZS ZoptEC) will be the fist FDA-approved drug for encometrial cancer (EC) in their Gynecologic Cancer page of their website ---- in the second paragraph of the heading named " Access To The Latest Treatments."
- Phase 2 prostate cancer met end point recently
- Macrilen Phase 3 results expected in November
Company has over $40 million in cash and no debt..
All the above equal to biggest deal in the stock market at these prices.
Warrant conversion will end and this puppy will fly
I agree....adding like crazy at these levels
They really don't have to report that. But they will tell you if you call them
NO..that's not the case.
Warrant conversion is very near the end. If you sell it's up to you, but you will be stepping on your nuts when you see AEZS gain 100%, 200%, 300% right before your eyes.
EAZS has a richer pipeline than many pharma's with a Billion market cap.
Once warrant conversions end AEZS will fly to fair value....what is fair value??....it's several times higher than what it is right now.
Right now AEZS is only trading at cash value or thereabouts because of the idiotic financial arrangement the company got into....but that idiocy is a blessing for us bottom feeders..
All the silly pumping and bashing is irrelevant until the warrant fully convert....and that days is coming REALLY soon
Obviously more qualified than any poster on this board
I've put him on ignore after reading a couple of his silly posts. You should do the same
Thank you...from reputable first-hand sources
(2) Investigator-driven and sponsored. We got the positive Phase 2 results last week. All pieces off the puzzle falling in place
Agree....he sounds like an elementary school kid
ZoptEC will be a blockbuster drug
Stupid comments like:
1 - BK in 2015.....why? because of dilution.....super stupid
2 - The SEC should not allow dilution.....What????
3 - Book Value Per Share (mrq): 0.07 stock is overpriced......garbage.....most biotecs have low book value
......and other stupid stuff
Are you really the author of those articles? They are actually pretty good.
What are your price targets on your next articles on AEZS. LPTN. ELTK, and GIG?